1346818-05-0

Basic information

• Product Name: 3-(1-(2,5-difluorophenyl)ethoxy)pyridin-2-amine
• Synonyms: 3-(1-(2,5-difluorophenyl)ethoxy)pyridin-2-amine
• CAS NO: 1346818-05-0
• Molecular Weight: 250.248
• Mol File: 1346818-05-0.mol

Chemical Properties

• CAS DataBase Reference: 3-(1-(2,5-difluorophenyl)ethoxy)pyridin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1-(2,5-difluorophenyl)ethoxy)pyridin-2-amine(1346818-05-0)
• EPA Substance Registry System: 3-(1-(2,5-difluorophenyl)ethoxy)pyridin-2-amine(1346818-05-0)

Safety Data

• Hazardous Substances Data: 1346818-05-0(Hazardous Substances Data)

Upstream product

• 3874-31-5 (RS)-1-(2,5-difluorophenyl)ethanol 
• 1346817-88-6 3-(1-(2,5-difluorophenyl)ethoxy)-2-nitropyridine 
• 1979-36-8 2',5'-difluoroacetophenone 
• 2646-90-4 2,5-difluorobenzaldehyde 

Downstream Products

• 1346818-36-7 5-bromo-3-(1-(2,5-difluorophenyl)ethoxy)pyridin-2-amine 
• 1613148-56-3 5-bromo-N,N-bis(tert-butoxycarbonyl)-3-(1-(2,5-difluorophenyl)ethoxy)pyridin-2-amine 
• 1613148-57-4 N,N-bis(tert-butoxycarbonyl)-3-(1-(2,5-difluorophenyl)ethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine 
• 1613148-58-5 N,N-bis(tert-butoxycarbonyl)-5-(5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-3-(1-(2,5-difluorophenyl)ethoxy)pyridin-2-amine 
• 1613148-55-2 3-(1-(2,5-difluorophenyl)ethoxy)-5-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)pyridin-2-amine 
• 1613148-60-9 3-(6-(bis(tert-butoxycarbonyl)amino)-5-(1-(2,5-difluorophenyl)ethoxy)pyridin-3-yl)-6-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-8-ol 
• 1613148-59-6 3-(6-amino-5-(1-(2,5-difluorophenyl)ethoxy)pyridin-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-8-ol 

Relevant articles and documents

Substituted pyridine compound and its method and use thereof

The invention relates to a novel substitutive pyridine compound, and a pharmaceutically acceptable salt and a pharmaceutical preparation of the substitutive pyridine compound for regulating the activity of protein kinases and regulating signal responses between cells or in the cells. Meanwhile, the invention further relates to a pharmaceutical composition containing the compound provided by the invention, and a method for treating high proliferative diseases of mammals, especially human with the pharmaceutical composition.

Substituted ring compound and its method and use thereof

The invention provides a substituted cyclic compound as well as a use method and application thereof. The compound is a compound as shown in a formula (I) or stereoisomers, stereomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound as shown in the formula (I). The invention further provides a medicament composition containing the compound. The compound and the medicament composition are capable of regulating the activity of protein kinase in a biological sample body and are used for protecting, treating or relieving proliferative diseases of patients. The formula (I) is as shown in the specification.

SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkynyl compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES

The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.